Market Analysis and Insights: Global Hematologic Malignancies Market
The global Hematologic Malignancies market size is projected to reach US$ 39360 million by 2026, from US$ 30650 million in 2020, at a CAGR of 4.3% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Hematologic Malignancies market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Hematologic Malignancies market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Hematologic Malignancies market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Hematologic Malignancies market.
Hematologic Malignancies Breakdown Data by Type
Leukemia
Lymphoma
Multiple Myeloma
Others
Hematologic Malignancies Breakdown Data by Application
Chemotherapy
Radiotherapy
Immunotherapy
Stem Cell Transplantation
Others
Based on regional and country-level analysis, the Hematologic Malignancies market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Hematologic Malignancies market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The following players are covered in this report:
Pfizer, Inc.
F. Hoffmann-LA Roche ltd
Sanofi-Aventis
Bristol-Myers Squibb Company
AbbVie, Inc.
Novartis AG
GlaxoSmithKline PLC
Celgene Corporation
Johnson & Johnson Services, Inc.
Takeda Pharmaceutical Company limited
The global Hematologic Malignancies market size is projected to reach US$ 39360 million by 2026, from US$ 30650 million in 2020, at a CAGR of 4.3% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Hematologic Malignancies market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Hematologic Malignancies market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Hematologic Malignancies market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Hematologic Malignancies market.
Hematologic Malignancies Breakdown Data by Type
Leukemia
Lymphoma
Multiple Myeloma
Others
Hematologic Malignancies Breakdown Data by Application
Chemotherapy
Radiotherapy
Immunotherapy
Stem Cell Transplantation
Others
Based on regional and country-level analysis, the Hematologic Malignancies market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Hematologic Malignancies market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The following players are covered in this report:
Pfizer, Inc.
F. Hoffmann-LA Roche ltd
Sanofi-Aventis
Bristol-Myers Squibb Company
AbbVie, Inc.
Novartis AG
GlaxoSmithKline PLC
Celgene Corporation
Johnson & Johnson Services, Inc.
Takeda Pharmaceutical Company limited
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hematologic Malignancies Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 Leukemia
1.2.3 Lymphoma
1.2.4 Multiple Myeloma
1.2.5 Others
1.3 Market by Application
1.3.1 Global Hematologic Malignancies Market Share by Application: 2020 VS 2026
1.3.2 Chemotherapy
1.3.3 Radiotherapy
1.3.4 Immunotherapy
1.3.5 Stem Cell Transplantation
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Hematologic Malignancies Market Perspective (2015-2026)
2.2 Global Hematologic Malignancies Growth Trends by Regions
2.2.1 Hematologic Malignancies Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Hematologic Malignancies Historic Market Share by Regions (2015-2020)
2.2.3 Hematologic Malignancies Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hematologic Malignancies Players by Market Size
3.1.1 Global Top Hematologic Malignancies Players by Revenue (2015-2020)
3.1.2 Global Hematologic Malignancies Revenue Market Share by Players (2015-2020)
3.2 Global Hematologic Malignancies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Hematologic Malignancies Revenue
3.4 Global Hematologic Malignancies Market Concentration Ratio
3.4.1 Global Hematologic Malignancies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hematologic Malignancies Revenue in 2019
3.5 Key Players Hematologic Malignancies Area Served
3.6 Key Players Hematologic Malignancies Product Solution and Service
3.7 Date of Enter into Hematologic Malignancies Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hematologic Malignancies Breakdown Data by Type (2015-2026)
4.1 Global Hematologic Malignancies Historic Market Size by Type (2015-2020)
4.2 Global Hematologic Malignancies Forecasted Market Size by Type (2021-2026)
5 Hematologic Malignancies Breakdown Data by Application (2015-2026)
5.1 Global Hematologic Malignancies Historic Market Size by Application (2015-2020)
5.2 Global Hematologic Malignancies Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Hematologic Malignancies Market Size (2015-2026)
6.2 North America Hematologic Malignancies Market Size by Type (2015-2020)
6.3 North America Hematologic Malignancies Market Size by Application (2015-2020)
6.4 North America Hematologic Malignancies Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Hematologic Malignancies Market Size (2015-2026)
7.2 Europe Hematologic Malignancies Market Size by Type (2015-2020)
7.3 Europe Hematologic Malignancies Market Size by Application (2015-2020)
7.4 Europe Hematologic Malignancies Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe
8 China
8.1 China Hematologic Malignancies Market Size (2015-2026)
8.2 China Hematologic Malignancies Market Size by Type (2015-2020)
8.3 China Hematologic Malignancies Market Size by Application (2015-2020)
8.4 China Hematologic Malignancies Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific
9 Japan
9.1 Japan Hematologic Malignancies Market Size (2015-2026)
9.2 Japan Hematologic Malignancies Market Size by Type (2015-2020)
9.3 Japan Hematologic Malignancies Market Size by Application (2015-2020)
9.4 Japan Hematologic Malignancies Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil
10 Southeast Asia
10.1 Southeast Asia Hematologic Malignancies Market Size (2015-2026)
10.2 Southeast Asia Hematologic Malignancies Market Size by Type (2015-2020)
10.3 Southeast Asia Hematologic Malignancies Market Size by Application (2015-2020)
10.4 Southeast Asia Hematologic Malignancies Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa
11 Key Players Profiles
11.1 Pfizer, Inc.
11.1.1 Pfizer, Inc. Company Details
11.1.2 Pfizer, Inc. Business Overview
11.1.3 Pfizer, Inc. Hematologic Malignancies Introduction
11.1.4 Pfizer, Inc. Revenue in Hematologic Malignancies Business (2015-2020))
11.1.5 Pfizer, Inc. Recent Development
11.2 F. Hoffmann-LA Roche ltd
11.2.1 F. Hoffmann-LA Roche ltd Company Details
11.2.2 F. Hoffmann-LA Roche ltd Business Overview
11.2.3 F. Hoffmann-LA Roche ltd Hematologic Malignancies Introduction
11.2.4 F. Hoffmann-LA Roche ltd Revenue in Hematologic Malignancies Business (2015-2020)
11.2.5 F. Hoffmann-LA Roche ltd Recent Development
11.3 Sanofi-Aventis
11.3.1 Sanofi-Aventis Company Details
11.3.2 Sanofi-Aventis Business Overview
11.3.3 Sanofi-Aventis Hematologic Malignancies Introduction
11.3.4 Sanofi-Aventis Revenue in Hematologic Malignancies Business (2015-2020)
11.3.5 Sanofi-Aventis Recent Development
11.4 Bristol-Myers Squibb Company
11.4.1 Bristol-Myers Squibb Company Company Details
11.4.2 Bristol-Myers Squibb Company Business Overview
11.4.3 Bristol-Myers Squibb Company Hematologic Malignancies Introduction
11.4.4 Bristol-Myers Squibb Company Revenue in Hematologic Malignancies Business (2015-2020)
11.4.5 Bristol-Myers Squibb Company Recent Development
11.5 AbbVie, Inc.
11.5.1 AbbVie, Inc. Company Details
11.5.2 AbbVie, Inc. Business Overview
11.5.3 AbbVie, Inc. Hematologic Malignancies Introduction
11.5.4 AbbVie, Inc. Revenue in Hematologic Malignancies Business (2015-2020)
11.5.5 AbbVie, Inc. Recent Development
11.6 Novartis AG
11.6.1 Novartis AG Company Details
11.6.2 Novartis AG Business Overview
11.6.3 Novartis AG Hematologic Malignancies Introduction
11.6.4 Novartis AG Revenue in Hematologic Malignancies Business (2015-2020)
11.6.5 Novartis AG Recent Development
11.7 GlaxoSmithKline PLC
11.7.1 GlaxoSmithKline PLC Company Details
11.7.2 GlaxoSmithKline PLC Business Overview
11.7.3 GlaxoSmithKline PLC Hematologic Malignancies Introduction
11.7.4 GlaxoSmithKline PLC Revenue in Hematologic Malignancies Business (2015-2020)
11.7.5 GlaxoSmithKline PLC Recent Development
11.8 Celgene Corporation
11.8.1 Celgene Corporation Company Details
11.8.2 Celgene Corporation Business Overview
11.8.3 Celgene Corporation Hematologic Malignancies Introduction
11.8.4 Celgene Corporation Revenue in Hematologic Malignancies Business (2015-2020)
11.8.5 Celgene Corporation Recent Development
11.9 Johnson & Johnson Services, Inc.
11.9.1 Johnson & Johnson Services, Inc. Company Details
11.9.2 Johnson & Johnson Services, Inc. Business Overview
11.9.3 Johnson & Johnson Services, Inc. Hematologic Malignancies Introduction
11.9.4 Johnson & Johnson Services, Inc. Revenue in Hematologic Malignancies Business (2015-2020)
11.9.5 Johnson & Johnson Services, Inc. Recent Development
11.10 Takeda Pharmaceutical Company limited
11.10.1 Takeda Pharmaceutical Company limited Company Details
11.10.2 Takeda Pharmaceutical Company limited Business Overview
11.10.3 Takeda Pharmaceutical Company limited Hematologic Malignancies Introduction
11.10.4 Takeda Pharmaceutical Company limited Revenue in Hematologic Malignancies Business (2015-2020)
11.10.5 Takeda Pharmaceutical Company limited Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hematologic Malignancies Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 Leukemia
1.2.3 Lymphoma
1.2.4 Multiple Myeloma
1.2.5 Others
1.3 Market by Application
1.3.1 Global Hematologic Malignancies Market Share by Application: 2020 VS 2026
1.3.2 Chemotherapy
1.3.3 Radiotherapy
1.3.4 Immunotherapy
1.3.5 Stem Cell Transplantation
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Hematologic Malignancies Market Perspective (2015-2026)
2.2 Global Hematologic Malignancies Growth Trends by Regions
2.2.1 Hematologic Malignancies Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Hematologic Malignancies Historic Market Share by Regions (2015-2020)
2.2.3 Hematologic Malignancies Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hematologic Malignancies Players by Market Size
3.1.1 Global Top Hematologic Malignancies Players by Revenue (2015-2020)
3.1.2 Global Hematologic Malignancies Revenue Market Share by Players (2015-2020)
3.2 Global Hematologic Malignancies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Hematologic Malignancies Revenue
3.4 Global Hematologic Malignancies Market Concentration Ratio
3.4.1 Global Hematologic Malignancies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hematologic Malignancies Revenue in 2019
3.5 Key Players Hematologic Malignancies Area Served
3.6 Key Players Hematologic Malignancies Product Solution and Service
3.7 Date of Enter into Hematologic Malignancies Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hematologic Malignancies Breakdown Data by Type (2015-2026)
4.1 Global Hematologic Malignancies Historic Market Size by Type (2015-2020)
4.2 Global Hematologic Malignancies Forecasted Market Size by Type (2021-2026)
5 Hematologic Malignancies Breakdown Data by Application (2015-2026)
5.1 Global Hematologic Malignancies Historic Market Size by Application (2015-2020)
5.2 Global Hematologic Malignancies Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Hematologic Malignancies Market Size (2015-2026)
6.2 North America Hematologic Malignancies Market Size by Type (2015-2020)
6.3 North America Hematologic Malignancies Market Size by Application (2015-2020)
6.4 North America Hematologic Malignancies Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Hematologic Malignancies Market Size (2015-2026)
7.2 Europe Hematologic Malignancies Market Size by Type (2015-2020)
7.3 Europe Hematologic Malignancies Market Size by Application (2015-2020)
7.4 Europe Hematologic Malignancies Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe
8 China
8.1 China Hematologic Malignancies Market Size (2015-2026)
8.2 China Hematologic Malignancies Market Size by Type (2015-2020)
8.3 China Hematologic Malignancies Market Size by Application (2015-2020)
8.4 China Hematologic Malignancies Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific
9 Japan
9.1 Japan Hematologic Malignancies Market Size (2015-2026)
9.2 Japan Hematologic Malignancies Market Size by Type (2015-2020)
9.3 Japan Hematologic Malignancies Market Size by Application (2015-2020)
9.4 Japan Hematologic Malignancies Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil
10 Southeast Asia
10.1 Southeast Asia Hematologic Malignancies Market Size (2015-2026)
10.2 Southeast Asia Hematologic Malignancies Market Size by Type (2015-2020)
10.3 Southeast Asia Hematologic Malignancies Market Size by Application (2015-2020)
10.4 Southeast Asia Hematologic Malignancies Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa
11 Key Players Profiles
11.1 Pfizer, Inc.
11.1.1 Pfizer, Inc. Company Details
11.1.2 Pfizer, Inc. Business Overview
11.1.3 Pfizer, Inc. Hematologic Malignancies Introduction
11.1.4 Pfizer, Inc. Revenue in Hematologic Malignancies Business (2015-2020))
11.1.5 Pfizer, Inc. Recent Development
11.2 F. Hoffmann-LA Roche ltd
11.2.1 F. Hoffmann-LA Roche ltd Company Details
11.2.2 F. Hoffmann-LA Roche ltd Business Overview
11.2.3 F. Hoffmann-LA Roche ltd Hematologic Malignancies Introduction
11.2.4 F. Hoffmann-LA Roche ltd Revenue in Hematologic Malignancies Business (2015-2020)
11.2.5 F. Hoffmann-LA Roche ltd Recent Development
11.3 Sanofi-Aventis
11.3.1 Sanofi-Aventis Company Details
11.3.2 Sanofi-Aventis Business Overview
11.3.3 Sanofi-Aventis Hematologic Malignancies Introduction
11.3.4 Sanofi-Aventis Revenue in Hematologic Malignancies Business (2015-2020)
11.3.5 Sanofi-Aventis Recent Development
11.4 Bristol-Myers Squibb Company
11.4.1 Bristol-Myers Squibb Company Company Details
11.4.2 Bristol-Myers Squibb Company Business Overview
11.4.3 Bristol-Myers Squibb Company Hematologic Malignancies Introduction
11.4.4 Bristol-Myers Squibb Company Revenue in Hematologic Malignancies Business (2015-2020)
11.4.5 Bristol-Myers Squibb Company Recent Development
11.5 AbbVie, Inc.
11.5.1 AbbVie, Inc. Company Details
11.5.2 AbbVie, Inc. Business Overview
11.5.3 AbbVie, Inc. Hematologic Malignancies Introduction
11.5.4 AbbVie, Inc. Revenue in Hematologic Malignancies Business (2015-2020)
11.5.5 AbbVie, Inc. Recent Development
11.6 Novartis AG
11.6.1 Novartis AG Company Details
11.6.2 Novartis AG Business Overview
11.6.3 Novartis AG Hematologic Malignancies Introduction
11.6.4 Novartis AG Revenue in Hematologic Malignancies Business (2015-2020)
11.6.5 Novartis AG Recent Development
11.7 GlaxoSmithKline PLC
11.7.1 GlaxoSmithKline PLC Company Details
11.7.2 GlaxoSmithKline PLC Business Overview
11.7.3 GlaxoSmithKline PLC Hematologic Malignancies Introduction
11.7.4 GlaxoSmithKline PLC Revenue in Hematologic Malignancies Business (2015-2020)
11.7.5 GlaxoSmithKline PLC Recent Development
11.8 Celgene Corporation
11.8.1 Celgene Corporation Company Details
11.8.2 Celgene Corporation Business Overview
11.8.3 Celgene Corporation Hematologic Malignancies Introduction
11.8.4 Celgene Corporation Revenue in Hematologic Malignancies Business (2015-2020)
11.8.5 Celgene Corporation Recent Development
11.9 Johnson & Johnson Services, Inc.
11.9.1 Johnson & Johnson Services, Inc. Company Details
11.9.2 Johnson & Johnson Services, Inc. Business Overview
11.9.3 Johnson & Johnson Services, Inc. Hematologic Malignancies Introduction
11.9.4 Johnson & Johnson Services, Inc. Revenue in Hematologic Malignancies Business (2015-2020)
11.9.5 Johnson & Johnson Services, Inc. Recent Development
11.10 Takeda Pharmaceutical Company limited
11.10.1 Takeda Pharmaceutical Company limited Company Details
11.10.2 Takeda Pharmaceutical Company limited Business Overview
11.10.3 Takeda Pharmaceutical Company limited Hematologic Malignancies Introduction
11.10.4 Takeda Pharmaceutical Company limited Revenue in Hematologic Malignancies Business (2015-2020)
11.10.5 Takeda Pharmaceutical Company limited Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
